Innovent Biologics is planning a second filing for its dual GLP-1/glucagon agonist mazdutide in China, as it tries to carve out a share of a market currently dominated by Novo Nordisk and Eli Lilly.

Learn more about outdoor play for children. A new study shows that people with diabetes who have low muscle mass may have a higher risk of death from heart disease.